| Name | SNS 314 mesylate |
|---|---|
| Supplier | Tocris Bioscience |
| Catalog | 4075 |
| Prices | $225.00, $925.00 |
| Sizes | 10 mg, 50 mg |
| Function Type | Inhibitor |
| Cas Number | 1146618-41-8 |
| Chemical Name | N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]ureamethanesulfonate |
| Formula | C18H15ClN6OS2.CH3SO3H |
| Molecular Weight | 527.04 |
| Purity | >98 % |
| Description | Potent, ATP-competitive Aurora kinase inhibitor (IC 50 values are 3, 9 and 31 nM for Aurora C, A and B, respectively). Exhibits both in vitro and in vivo activity against human cancer cell lines and tumor xenograft models. Displays additive antiproliferative effects in combination with chemotherapeutics such as carboplatin (Cat. No. 2626), gemcitabine (Cat. No. 3259) and 5-fluorouracil (Cat. No. 3257). |
| Supplier Page | Shop |
Oslob JD, Romanowski MJ, Allen DA, Baskaran S, Bui M, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris S, Heumann SA, Hoch U, Jacobs JW, Lam J, Lawrence CE, McDowell RS, Nannini MA, Shen W, Silverman JA, Sopko MM, Tangonan BT, Teague J, Yoburn JC, Yu CH, Zhong M, Zimmerman KM, O'Brien T, Lew W. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4.
VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV. Mol Cancer Ther. 2009 Apr;8(4):930-9.
Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, Harris SO, Hashash A, Hoch U, Hogan JN, Howlett AR, Jacobs JW, Lam JW, Ritchie SC, Romanowski MJ, Silverman JA, Stockett DE, Teague JN, Zimmerman KM, Taverna P. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. doi: